Neuroprotection and thrombolysis: Combination therapy in acute ischaemic stroke

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 12, 2006, Pages 1571-1581

  Ly, John V ^a   Zavala, Jorge A ^a   Donnan, Geoffrey A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cerebral ischaemia; Combination therapy; Ischaemic cascade; Neuroprotection; Penumbra; Stroke; Thrombolysis

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ACETYLSALICYLIC ACID; ALTEPLASE; CALCIUM CHANNEL BLOCKING AGENT; CEREBROLYSIN; CITICOLINE; CLOMETHIAZOLE; DISUFENTON SODIUM; DIZOCILPINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FOSPHENYTOIN SODIUM; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; MAGNESIUM SULFATE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NEUTROPHIL INHIBITORY FACTOR; NIMODIPINE; PLACEBO; SCAVENGER; SODIUM CHANNEL BLOCKING AGENT; TENECTEPLASE; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR; UK 279276; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; HYPOTENSION; INDUCED HYPOTHERMIA; INFECTION; MEMBRANE STABILIZATION; META ANALYSIS; NERVE INJURY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BENZENESULFONATES; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; GABA AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; NITROGEN OXIDES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; SODIUM CHANNEL BLOCKERS; THIAZOLES; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33747033469     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.12.1571     Document Type: Review

References (67)

1. BONITA R: Epidemiology of stroke. Lancet (1992) 339:342-344.
2. INGALL T: Stroke-incidence, mortality, morbidity and risk. J. Insur. Med. (2004) 36(2):143-152.
3. ASPLUND K: What MONICA told us about stroke. Lancet Neurol. (2005) 4(1):64-68.
4. ALBERTS MJ: tPA in acute ischemic stroke: United States experience and issues for the future. Neurology (1998) 51(3 Suppl. 3):S53-S55.
5. DONNAN GA, DAVIS SM, LEVI CR: Strategies to improve outcomes after acute stroke. Med. J. Aust. (2003) 178(7):309-310.
6. OGDEN K CD, PEARCE D: Australian survey of hospital services for stroke. Cerebrovasc. Dis. (2001) 11(Suppl. 4):A93.
7. GROTTA JC, BURGIN WS, EL-MITWALLI A et al.: Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch. Neurol. (2001) 58(12):2009-2013.
8. HEISS WD: Ischemic penumbra: evidence from functional imaging in man. J. Cereb. Blood Flow Metab. (2000) 20:1276-1293.
9. ASTRUP J, SIESJO BK, SYMON L: Thresholds in cerebral ischemia - the ischemic penumbra. Stroke (1981) 12(6):723-725.
10. DAVIS SM, DONNAN GA, BUTCHER KS, PARSONS M: Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr. Opin. Neurol. (2005) 18(1):47-52.
11. DONNAN GA, DAVIS SM: Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol. (2002) 1(7):417-425.
12. HEISS WD, GRAF R: The ischemic penumbra. Curr Opin. Neurol. (1994) 7(1):11-19.
13. GINSBERG MD: Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke (2003) 34(1):214-223.
14. MARKUS R, REUTENS DC, KAZUI S et al.: Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain (2004) 127(Pt 6):1427-1436.
15. WINTERMARK M, REICHHART M, CUISENAIRE O et al.: Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke (2002) 33(8):2025-2031.
16. WINTERMARK M, FLANDERS AE, VELTHUIS B et al.: Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke (2006) 37(4):979-985.
17. HACKE W, DONNAN G, FIESCHI C et al.: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363:768-774.
18. SCHALLER B, GRAF R: Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J. Cereb. Blood Flow Metab. (2004) 24(4):351-371.
19. MERGENTHALER P, DIRNAGL U, MEISEL A: Pathophysiology of stroke: lessons from animal models. Metab. Brain Dis. (2004) 19(3-4):151-167.
20. DIRNAGL U, IADECOLA C, MOSKOWITZ MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. (1999) 22(9):391-397.
21. LO EH, DALKARA T, MOSKOWITZ MA: Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. (2003) 4(5):399-415.
22. KIDWELL CS, LIEBESKIND DS, STARKMAN S, SAVER JL: Trends in acute ischemic stroke trials through the 20th century. Stroke (2001) 32(6):1349-1359.
23. HORN J, DE HAAN RJ, VERMEULEN M, LIMBURG M: Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke (2001) 32(2):461-465.
24. GANDOLFO C, SANDERCOCK P, CONTI M: Lubeluzole for acute ischaemic stroke. Cochrane Database Syst. Rev. (2002) (1):CD001924.
25. GROTTA J: Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke (1997) 28(12):2338-2346.
26. DIENER HC, CORTENS M, FORD G et al.: Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke (2000) 31(11):2543-2551.
27. GROTTA J: Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis. (2001) 12(3):258-263.
28. WAHLGREN NG, RANASINHA KW, ROSOLACCI T et al.: Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke (1999) 30(1):21-28.
29. LYDEN P, SHUAIB A, NG K et al.: Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke (2002) 33(1):122-128.
30. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS): the RANTTAS Investigators. Stroke (1996) 27(9):1453-1458.
31. HALEY EC Jr: High-dose tirilazad for acute stroke (RANTTAS II) RANTTAS II Investigators. Stroke (1998) 29(6):1256-1257.
32. VAN DER WORP HB, KAPPELLE LJ, ALGRA A et al.: The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology (2002) 58(1):133-135.
33. LEES KR, BARER D, FORD GA et al.: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke (2003) 34(2):482-487.
34. LEES KR, SHARMA AK, BARER D et al.: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke (2001) 32(3):675-680.
35. LEES KR, ZIVIN JA, ASHWOOD T et al.: NXY-059 for acute ischemic stroke. N. Engl. J. Med. (2006) 354(6):588-600.
36. DAVIS SM, LEES KR, ALBERS GW et al.: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 31(2):347-354.
37. MUIR KW, LEES KR, FORD I, DAVIS S: Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet (2004) 363(9407):439-445.
38. SAVER JL, KIDWELL C, ECKSTEIN M, STARKMAN S: Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy - Magnesium (FAST - MAG) pilot trial. Stroke (2004) 35(5):e106-e108.
39. CLARK WM, WARACH SJ, PETTIGREW LC, GAMMANS RE, SABOUNJIAN LA: A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology (1997) 49(3):671-678.
40. CLARK WM, WILLIAMS BJ, SELZER KA et al.: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke (1999) 30(12):2592-2597.
41. CLARK WM, WECHSLER LR, SABOUNJIAN LA, SCHWIDERSKI UE: A Phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology (2001) 57(9):1595-602.
42. WARACH S, PETTIGREW LC, DASHE JF et al.: Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann. Neurol. (2000) 48(5):713-722.
43. ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology (2001) 57(8):1428-1434.
44. LADURNER G, KALVACH P, MOESSLER H: Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J. Neural Transm. (2005) 112(3):415-428.
45. DE GEORGIA MA, KRIEGER DW, ABOU-CHEBL A et al.: Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology (2004) 63(2):312-317.
46. TAKAHASHI M, MACDONALD RL: Vascular aspects of neuroprotection. Neurol. Res. (2004) 26(8):862-869.
47. BARBER PA, DAVIS SM, INFELD B et al.: Spontaneous reperfusion after ischemic stroke is associated with improved outcome. Stroke (1998) 29(12):2522-2528.
48. XUE D, SLIVKA A, BUCHAN AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke (1992) 23(6):894-899.
49. BATH P: Re: Stroke Therapy Academic Industry Roundtable II (STAIR-II). Stroke (2002) 33(2):639-640.
50. ZHANG L, ZHANG ZG, ZHANG C, ZHANG RL, CHOPP M: Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke (2004) 35(12):2890-2895.
51. ANDERSEN M, OVERGAARD K, MEDEN P, BOYSEN G, CHOI SC: Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke (1999) 30(7):1464-1471.
52. SHUAIB A, YANG Y, LI Q: Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. Exp. Neurol. (2000) 161(2):733-739.
53. BOWES MP, ROTHLEIN R, FAGAN SC, ZIVIN JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology (1995) 45(4):815-819.
54. ZHANG RL, ZHANG ZG, CHOPP M, ZIVIN JA: Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke (1999) 30(3):624-629.
55. LEKIEFFRE D, BENAVIDES J, SCATTON B, NOWICKI JP: Neutoprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res. (1997) 776(1-2):88-95.
56. SEREGHY T, OVERGAARD K, BOYSEN G: Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke (1993) 24(11):1702-1708.
57. HALLENBECK JM, DUTKA AJ: Background review and current concepts of reperfusion injury. Arch. Neurol. (1990) 47(11):1245-1254.
58. WARACH S, LATOUR LL: Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke (2004) 35(11 Suppl. 1):2659-2661.
59. KIDWELL CS, SAVER JL, STARKMAN S et al.: Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann. Neurol. (2002) 52(6):698-703.
60. KRAMS M, LEES KR, HACKE W et al.: Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 34(11):2543-2548.
61. LYDEN P, JACOBY M, SCHIM J et al.: The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology (2001) 57(7):1199-205.
62. SANDERCOCK P, GUBITZ G, FOLEY P, COUNSELL C: Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst. Rev. (2003) (2):CD000029.
63. LANGHORNE P, WILLIAMS BO, GILCHRIST W, HOWIE K: Do stroke units save lives? Lancet (1993) 342(8868):395-398.
64. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. (1995) 333(24):1581-1587.
65. BARBER PA, ZHANG J, DEMCHUK AM, HILL MD, BUCHAN AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 56(8):1015-1020.
66. BROADLEY SA, THOMPSON PD: Time to hospital admission for acute stroke: an observational study. Med. J. Aust. (2003) 178(7):329-331.
67. HERNANDEZ LA, GRISHAM MB, TWOHIG B et al.: Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am. J. Physiol. (1987) 253(3 Pt 2):H699-H703.